


Attorney Docket **044574-5059-US**
Application No. **Not Assigned**
Page 2

If there are any other fees due in connection with the filing of this Preliminary Amendment, please charge the fees to our Deposit Account No. 13-4520. If a fee is required for an extension of time under 37 C.F.R. § 1.136 not accounted for above, such an extension is requested and the fee should also be charged to our Deposit Account.

Date: **May 30, 2001**
Morgan, Lewis & Bockius LLP
Customer No. **009629**
1800 M Street, N.W.
Washington, D.C. 20036-5869

Respectfully submitted,
Morgan, Lewis & Bockius LLP



Michael S. Tuscan
Registration No. 43,210

Attorney Docket 044574-5059-US
Application No. Not Assigned
Page 3

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Claims 10, 25, 28 & 29 have been amended as follows:

10. (Once Amended) The vector of [~~any one of claims~~] claim 1[-9], wherein the vector is an adenovirus vector.

25. (Once Amended) The method of [~~any one of claims 20-24~~] either claims 21 or 23, wherein the gene is selected from the group consisting of a thymidine kinase, cytosine deaminase, a purine nucleotide phosphorylase, a nitroreductase, β -galactosidase, a cytochrome P450 reductase, a carboxylesterase, a deoxycytidine kinase and a thymidine phosphorylase.

28. (Once Amended) The method of [~~any one of claims 20-24~~] either claims 21 or 23, wherein at least about 5% of the cells are infected.

29. (Once Amended) A recombinant adenovirus comprising the vector of [~~claims~~] claim 1[-9].